Transaction #8710 · Form 4 · 0001061983-25-000036
CYTOKINETICS INC · Stock award · Common Stock
CYTOKINETICS INC · Transacted November 14, 2025 · Filed November 17, 2025
What does this filing report?
An SEC Form 4 filing for CYTOKINETICS INC records a stock award involving Common Stock on November 14, 2025. The reported quantity was 87,297. The filing date is November 17, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- CYTOKINETICS INC
- Company CIK
- 0001061983
- Security type
- Non-derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 87,297
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 87,297
- Ownership description
- Not reported
- SEC acceptance time
- Nov 17, 2025, 4:02 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Hessekiel Jeffrey ↗
Chief Legal & Admin Officer
CIK 0001599803
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Initial new hire grant comprised of restricted stock units ("RSUs") that are convertible to shares of common stock on a 1:1 basis upon vesting. RSUs will vest as follows: 40% of the aggregate RSUs on the date falling 1-year from the date of grant, an additional 40% of the aggregate RSUs on the date falling 2-years from the date of grant, and the remaining 20% of the aggregate RSUs on the date falling 3-years from the date of grant, in each case subject to Mr. Hessekiel's continued employment with Cytokinetics.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.